Maxalt-mlt and Nausea - a phase IV clinical study of FDA data

Summary:

Nausea is reported as a side effect among people who take Maxalt-mlt (rizatriptan benzoate), especially for people who are female, 50-59 old, have been taking the drug for 1 - 2 years also take Ambien, and have Narcolepsy.

The phase IV clinical study analyzes which people have Nausea when taking Maxalt-mlt. It is created by eHealthMe based on reports of 1,245 people who have side effects when taking Maxalt-mlt from the FDA, and is updated regularly.

What is Maxalt-mlt?

Maxalt-mlt has active ingredients of rizatriptan benzoate. It is often used in migraine. eHealthMe is studying from 1,534 Maxalt-mlt users. Check the latest studies of Maxalt-mlt.

What is Nausea?

Nausea (feeling of having an urge to vomit) is found to be associated with 3,878 drugs and 5,633 conditions by eHealthMe. Check the latest studies of Nausea.

On Jul, 13, 2026

1,245 people reported to have side effects when taking Maxalt-mlt.
Among them, 123 people (9.88%) have Nausea.

Among these 123 people:

* Approximation only. Some reports may have incomplete information.

Do you take Maxalt-mlt and have Nausea?

- Check whether Nausea is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Maxalt-mlt:

Maxalt-mlt (1,534 reports)

Nausea treatments and more:

Nausea (962,089 reports)

How severe was Nausea and when was it recovered:

Nausea in Maxalt-mlt

Expand to all the drugs that have ingredients of rizatriptan benzoate:

Nausea and drugs with ingredients of rizatriptan benzoate (2,106 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Maxalt-mlt:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nausea:

Nausea (3,878 drugs)

Browse all the conditions that are associated with Nausea:

Nausea (5,633 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on rizatriptan benzoate (the active ingredients of Maxalt-mlt) and Maxalt-mlt (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.